Newron Enters Make-or-Break Phase for Evenamide With Fresh Capital and Renewed Leadership

Newron rebuilds finances and appoints new chairman as pivotal ENIGMA-TRS 2 data nears; FDA clinical hold adds risk but analysts remain bullish with average target near 47 CHF.

Newron SpA is approaching a defining moment for its schizophrenia drug candidate Evenamide, with financial buffers rebuilt and a new chairman in place just months before pivotal clinical data are due. The Italian biopharma company has raised €38 million through a share placement in February and extended a loan agreement with the European Investment Bank to June 2028, ensuring it can fund operations beyond the expected top?line readout from the ENIGMA?TRS 2 study in the fourth quarter of this year.

The Phase III programme is the centrepiece of Newron’s investment case. ENIGMA?TRS 1, a one?year, double?blind, placebo?controlled trial, began enrolling patients in August 2025 and targets at least 600 participants. The shorter ENIGMA?TRS 2, launched last December, tests Evenamide 15 mg twice daily as an add?on to existing antipsychotics in patients with treatment?resistant schizophrenia. Combined, the two studies involve more than 1,000 patients globally. Evenamide, a novel glutamate modulator, could become the first adjunctive therapy specifically approved for this hard?to?treat population, which accounts for an estimated one?third to one?half of all schizophrenia patients.

Yet the story is not without risk. In late April, the US Food and Drug Administration placed a clinical hold on patient enrolment in the pivotal study after a death. H.C. Wainwright trimmed its price target from 48 to 44 Swiss francs in response, though analysts remain constructive overall. The average target now stands at 47.01 Swiss francs, according to the primary source, while a separate count of four newly covering analysts sets the consensus close to 49 Swiss francs. No sell recommendations are outstanding.

The stock has felt the weight of the FDA action. After closing at €15.70 on Friday, the share sits 0.63% lower on the day and has lost 15.82% over the past month. Year?to?date, the decline is roughly 41%, leaving the price little more than half its January peak. But the long?term picture is starkly different: the 12?month gain is 82.56%, producing annualised volatility near 75%.

Newron has also refreshed its board. At the annual general meeting, shareholders elected Chris Martin as chairman, succeeding Ulrich Köstlin, and confirmed George Garibaldi and Paolo Zocchi as new supervisory board members. The changes come as the company prepares to present at the BIO International Convention in San Diego from 22 to 25 June, where it will seek to advance its US commercialisation strategy.

In Asia, a parallel Phase III study was initiated in January 2026 by EA Pharma, a unit of the Eisai group, which holds development, manufacturing and marketing rights for Japan and other Asian markets. That parallel track broadens the data base but also raises expectations for a consistent outcome.

For investors, the near?term catalyst is clear: if ENIGMA?TRS 2 delivers positive results without further FDA delays, the current valuation discount could narrow. Conversely, a prolonged hold in the US would keep the stock under pressure. All eyes are now on San Diego and, ultimately, on the fourth?quarter readout that will determine whether Evenamide can live up to its promise.